Home › Merck Provides Update on Investigational 9-valent HPV Vaccine V503 to U.S. Advisory Committee on Immunization Practices
 

Keywords :   


Merck Provides Update on Investigational 9-valent HPV Vaccine V503 to U.S. Advisory Committee on Immunization Practices

2013-10-24 16:27:00| Merck.com - Research & Development News

Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today provided an overview of the clinical trial program for V503, the companys investigational 9-valent human papillomavirus (HPV) vaccine, to the Advisory Committee on Immunization Practices in the United States. Merck said that the pivotal efficacy trial is complete, the primary endpoints have been met and the company expects to submit a Biologics License Application for V503 to the U.S. Language: English Contact: MerckMedia:Pamela Eisele, (908) 423-5042Imraan Munshi, (215) 652-0059Investor:Carol Ferguson, (908) 423-4465Justin Holko, (908) 423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: update committee practices advisory

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
29.09Hurricane Isaac Graphics
29.09Hurricane Isaac Forecast Discussion Number 13
29.09Tropical Storm Joyce Graphics
29.09Hurricane Isaac Wind Speed Probabilities Number 13
29.09Hurricane Isaac Public Advisory Number 13
29.09Summary for Hurricane Isaac (AT5/AL102024)
29.09Tropical Storm Joyce Wind Speed Probabilities Number 7
29.09Tropical Storm Joyce Forecast Discussion Number 7
More »